Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

医学 无容量 易普利姆玛 中止 内科学 微卫星不稳定性 癌症 临床终点 胃肠病学 临床研究阶段 不利影响 进行性疾病 肿瘤科 免疫疗法 疾病 化疗 随机对照试验 等位基因 化学 微卫星 基因 生物化学
作者
Hisato Kawakami,Shigenori Kadowaki,Akitaka Makiyama,Masahiro Tsuda,Kenro Hirata,Naotoshi Sugimoto,Nozomu Machida,Hiroki Hara,Hidekazu Hirano,Taito Esaki,Yoshito Komatsu,Shuichi Hironaka,Yukari Kobayashi,Kazuhiro Kakimi,Yasutaka Chiba,Narikazu Boku,Ichinosuke Hyodo,Kei Muro
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (19): 2184-2195 被引量:20
标识
DOI:10.1200/jco-24-02463
摘要

PURPOSE: Microsatellite instability-high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) ipilimumab (IPI) for first-line treatment of MSI-H AGC. PATIENTS AND METHODS: Patients with MSI-H AGC received NIVO (240 mg once every 2 weeks) and IPI (1 mg/kg once every 6 weeks). The primary end point was overall response rate (ORR) assessed by blinded independent central review. Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis. MSI-H status was confirmed with an MSI-IVD Kit (Falco). RESULTS: Twenty-nine patients were enrolled. The ORR was 62.1% (95% CI, 42.3 to 79.3), with a complete response rate of 10.3%. The DCR was 79.3% (95% CI, 60.3 to 92.0). Treatment-related adverse events (TRAEs) of any grade occurred in 93.1% of patients, with those of grade ≥3 manifesting in 37.9% of patients. At the data cutoff (median follow-up of 9.0 months), treatment had been discontinued in 21 patients, with such discontinuation being due to TRAEs in 12 (41.4%) patients. However, after exclusion of one patient with progressive disease, the remaining 11 patients showed long-term antitumor efficacy after treatment discontinuation (range of response duration, 0.9+ to 15.6+ months). The median PFS was 13.8 months (95% CI, 13.7 months to not reached [NR]) and the median OS was NR (95% CI, 13.7 months to NR), with a 12-month OS rate of 79.5%. CONCLUSION: NIVO plus LD-IPI showed robust and durable antitumor efficacy as a first-line treatment for MSI-H AGC. Although TRAEs often led to treatment discontinuation, treatment efficacy was subsequently sustained in most patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
molihuakai的应助被Steve采纳,获得10
刚刚
老实的海发布了新的文献求助10
刚刚
艺想天开发布了新的文献求助10
刚刚
123完成签到 ,获得积分10
刚刚
姜惠完成签到,获得积分10
刚刚
神勇友灵完成签到,获得积分10
2秒前
滴滴答答完成签到,获得积分10
2秒前
槑槑完成签到 ,获得积分10
2秒前
爱吃橙子的草莓熊完成签到 ,获得积分10
2秒前
11111完成签到,获得积分10
2秒前
津津乐道完成签到,获得积分10
2秒前
我谈完成签到,获得积分10
3秒前
椰子完成签到,获得积分10
3秒前
bdsb完成签到,获得积分10
3秒前
想想完成签到,获得积分10
3秒前
ll完成签到 ,获得积分10
3秒前
qin发布了新的文献求助10
4秒前
lc完成签到,获得积分10
4秒前
CXWjh关注了科研通微信公众号
4秒前
luojh03发布了新的文献求助10
4秒前
xdw发布了新的文献求助10
5秒前
魏子合完成签到 ,获得积分10
5秒前
ChangzhenSong完成签到,获得积分10
5秒前
njzqs完成签到,获得积分10
5秒前
文献互助完成签到,获得积分10
6秒前
lshao完成签到 ,获得积分10
6秒前
6秒前
沉默是金完成签到,获得积分10
6秒前
坦率的蜜蜂完成签到,获得积分10
7秒前
mxm完成签到,获得积分10
7秒前
fighting完成签到 ,获得积分10
7秒前
王小美完成签到,获得积分10
7秒前
8秒前
8秒前
dd发布了新的文献求助10
8秒前
清爽博超完成签到,获得积分10
8秒前
123qwe完成签到,获得积分10
9秒前
悠南完成签到 ,获得积分10
9秒前
Ray完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173580
求助须知:如何正确求助?哪些是违规求助? 9565737
关于积分的说明 21782083
捐赠科研通 7767775
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476870